Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 16/20 | 0.45 |
| ▸ | KDR | P35968 | 8/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792573 | 0.89 | TGFBR1 (0.45) | USP7TGFBR1KDRMAPK14 | |
| SCHEMBL5788266 | 0.87 | TGFBR1 (0.43) | TGFBR1KDRMAPK14GAAHTT | |
| SCHEMBL6335287 | 0.84 | GAA (0.49) | TGFBR1KDRMAPK14GAASMN1; SMN2 | |
| SCHEMBL5786499 | 0.84 | BACE1 (0.40) | TGFBR1KDRMAPK14GAAHTT | |
| SCHEMBL5790085 | 0.84 | TGFBR1 (0.46) | TGFBR1KDRMAPK14MAPT | |
| SCHEMBL5787113 | 0.83 | GAA (0.41) | TGFBR1KDRMAPK14GAAHTT | |
| SCHEMBL5790048 | 0.82 | TGFBR1 (0.38) | TGFBR1KDRMAPK14MAPT | |
| SCHEMBL5788683 | 0.82 | USP7 (0.48) | USP7TGFBR1KDRMAPK14GAA | |
| SCHEMBL5791728 | 0.81 | SMN1; SMN2 (0.49) | TGFBR1KDRMAPK14GAASMN1; SMN2 | |
| SCHEMBL5788026 | 0.81 | HRH3 (0.49) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | USP7 4477/4885TGFBR1 4/4885KDR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.